ATE548381T1 - Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus - Google Patents

Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus

Info

Publication number
ATE548381T1
ATE548381T1 AT09765524T AT09765524T ATE548381T1 AT E548381 T1 ATE548381 T1 AT E548381T1 AT 09765524 T AT09765524 T AT 09765524T AT 09765524 T AT09765524 T AT 09765524T AT E548381 T1 ATE548381 T1 AT E548381T1
Authority
AT
Austria
Prior art keywords
polypeptides
epo
pharmaceutical compositions
protease resistance
modified
Prior art date
Application number
AT09765524T
Other languages
English (en)
Inventor
Thierry Guyon
Gilles Borrelly
Xavier Gallet
Lila Drittanti
Manuel Vega
Original Assignee
Hanall Biopharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanall Biopharma Co Ltd filed Critical Hanall Biopharma Co Ltd
Application granted granted Critical
Publication of ATE548381T1 publication Critical patent/ATE548381T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT09765524T 2008-05-29 2009-05-29 Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus ATE548381T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13037608P 2008-05-29 2008-05-29
PCT/EP2009/003862 WO2009152944A1 (en) 2008-05-29 2009-05-29 Modified erythropoietin (epo)polypeptides that exhibit increased protease resistance and pharmaceutical compositions thereof

Publications (1)

Publication Number Publication Date
ATE548381T1 true ATE548381T1 (de) 2012-03-15

Family

ID=40943614

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09765524T ATE548381T1 (de) 2008-05-29 2009-05-29 Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus

Country Status (7)

Country Link
US (1) US20120264686A9 (de)
EP (1) EP2297197B1 (de)
JP (1) JP2011520472A (de)
KR (1) KR101275950B1 (de)
CN (1) CN102186879A (de)
AT (1) ATE548381T1 (de)
WO (1) WO2009152944A1 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
JP2010510794A (ja) 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
US9321999B2 (en) * 2009-11-19 2016-04-26 Solis Biodyne Oü Compositions for increasing polypeptide stability and activity, and related methods
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
MX2013003681A (es) 2010-10-01 2013-11-20 Moderna Therapeutics Inc Ácidos nucleicos manipulados y métodos de uso de los mismos.
CN103649126B (zh) * 2011-01-19 2016-11-09 菲卢马克斯制药公司 用于调节铁稳态的组合物及其使用方法
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
SI3682905T1 (sl) 2011-10-03 2022-04-29 Modernatx, Inc. Modificirani nukleozidi, nukleotidi in nukleinske kisline ter njihove uporabe
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
SI2922554T1 (sl) 2012-11-26 2022-06-30 Modernatx, Inc. Terminalno modificirana RNA
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
SG11201602503TA (en) 2013-10-03 2016-04-28 Moderna Therapeutics Inc Polynucleotides encoding low density lipoprotein receptor
EP3194429A4 (de) * 2014-09-18 2018-06-13 Askgene Pharma, Inc. Neuartige feline erythropoietinrezeptor-agonisten
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
KR101947342B1 (ko) * 2017-05-05 2019-02-12 주식회사 유비프로틴 Gm-csf 반감기를 증가시키는 방법
CN107898812A (zh) * 2017-12-06 2018-04-13 广州瑞铂茵健康管理咨询有限公司 一种基于脐带干细胞及活性成分的软骨损伤混合修复液
CN110093336B (zh) * 2018-01-29 2023-03-24 上海雅心生物技术有限公司 一种稳定的胰蛋白酶及其制备方法
WO2019173283A1 (en) 2018-03-05 2019-09-12 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
CN110241130B (zh) * 2018-03-09 2023-04-14 中国科学院分子植物科学卓越创新中心 控制植物粒数和粒重的gsn1基因、编码蛋白及其应用
AR113091A1 (es) 2018-09-27 2020-01-22 Univ Nacional Del Litoral Eritropoyetina humana modificada
CA3174377A1 (en) * 2020-04-09 2021-10-14 Samuel Newton Sathyanesan Compositions comprising recombinant epo and methods of use thereof
CA3176807A1 (en) * 2020-05-01 2021-11-04 Sacha Gnjatic Compositions and methods for preventing, detecting, and treating inflammatory bowel disease
EP3916008A1 (de) * 2020-05-26 2021-12-01 Sylus Co., Ltd. Neues peptid und verwendung davon zur behandlung von erkrankungen des gehirns und nervensystems
MX2023003700A (es) * 2020-09-30 2023-04-21 Realta Life Sciences Inc Peptidos y metodos de uso.
JP2023550742A (ja) * 2020-11-18 2023-12-05 チュラポーン ファンデーション エリスロポエチンバリアント及びその使用
WO2022159414A1 (en) 2021-01-22 2022-07-28 University Of Rochester Erythropoietin for gastroinfestinal dysfunction
CN117069825A (zh) * 2022-05-17 2023-11-17 广州汉腾生物科技有限公司 重组促红细胞生成素及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03151399A (ja) * 1989-11-07 1991-06-27 Snow Brand Milk Prod Co Ltd 変異ヒトエリスロポエチン
PA8536201A1 (es) * 2000-12-29 2002-08-29 Kenneth S Warren Inst Inc Protección y mejoramiento de células, tejidos y órganos que responden a la eritropoyetina
CA2437272A1 (en) * 2001-02-06 2002-08-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Modified erythropoietin (epo) with reduced immunogenicity
AU2002351746A1 (en) * 2001-12-21 2003-07-15 Maxygen Aps Erythropoietin conjugates
US20050202438A1 (en) 2002-09-09 2005-09-15 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
US20060020396A1 (en) 2002-09-09 2006-01-26 Rene Gantier Rational directed protein evolution using two-dimensional rational mutagenesis scanning
EP1539950A1 (de) 2002-09-09 2005-06-15 Nautilus Biotech Rationelle gerichtete eiweiss evolution durch zweidimensionale rationelle mutagenese-abtastung
CN100405906C (zh) * 2002-10-09 2008-07-30 尼奥斯技术有限公司 促红细胞生成素:促红细胞生成素的重构和糖缀合
US20040091961A1 (en) * 2002-11-08 2004-05-13 Evans Glen A. Enhanced variants of erythropoietin and methods of use
JP2008508854A (ja) * 2004-04-23 2008-03-27 ケンブリッジ アンティボディー テクノロジー リミテッド エリスロポイエチンタンパク質変異体
WO2006029094A2 (en) * 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
GB0500099D0 (en) * 2005-01-05 2005-02-09 Cambridge Antibody Tech Methods and means relating to protein variants
JP2010510794A (ja) * 2006-11-28 2010-04-08 ハナル ファーマシューティカル カンパニー リミテッド 修飾型エリスロポエチンポリペプチド及びこの治療用用途
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides

Also Published As

Publication number Publication date
KR20110022638A (ko) 2011-03-07
US20120264686A9 (en) 2012-10-18
EP2297197A1 (de) 2011-03-23
CN102186879A (zh) 2011-09-14
KR101275950B1 (ko) 2013-06-25
US20120094906A1 (en) 2012-04-19
WO2009152944A1 (en) 2009-12-23
JP2011520472A (ja) 2011-07-21
EP2297197B1 (de) 2012-03-07

Similar Documents

Publication Publication Date Title
ATE548381T1 (de) Modifizierte erythropoietin (epo)-polypeptide mit erhöhter proteaseresistenz und pharmazeutische zusammensetzungen daraus
WO2008065372A3 (en) Modified erythropoietin polypeptides and uses thereof for treatment
EA201171220A1 (ru) Мутанты fgf21 и их применение
EA201001883A1 (ru) Мутанты fgf21 и их применение
CY1121327T1 (el) Τροποποιημενα αντισωματα anti-il-23p19
WO2007110231A3 (en) MODIFIED INTERFERON-β (IFN-β) POLYPEPTIDES
BR112012017345A2 (pt) "composições e métodos de pgl para a produção aumentada de isopreno e outros produtos com 6-fosfogliconolactonase (pgl)"
MX390894B (es) Polipéptido de fusión anti-cáncer.
MX2011013903A (es) Polipeptidos quimericos y usos de los mismos.
EP2568996A4 (de) Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von phenylalanyl-beta-trna-synthetasen
NO20082531L (no) Neuropilinantagonister
EP2563912A4 (de) Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von asparaginyl-trna-synthetasen
EP4241784A3 (de) Künstliche nukleinsäuremoleküle zur verbesserten proteinexpression
BRPI0609797B8 (pt) nanocorpos melhorados para o tratamento de desordens mediadas por agregação
BR112014022708A8 (pt) uso de uma proteína ligante de neurotrofina p75ntr, uso de uma molécula de ácido nucleico, uso de um vetor de expressão replicável, célula hospedeira, composição farmacêutica e kit
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
CL2007003629A1 (es) Compuestos heterociclicos aril-sustituidos, moduladores del receptor de cannabinoides tipo i (cb1); proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como trastornos metabolicos y trastornos cognitivos.
WO2007133835A3 (en) Ras mutation and compositions and methods related thereto
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
CY1110860T1 (el) Αναστροφη μεταγραφαση τελομερασης πτηνου
MY177970A (en) Bcma (cd269/tnfrsf17) -binding proteins
EA201990619A1 (ru) Fgf21 мутанты и их применение
BR112012025568A2 (pt) proteínas de ligação ao tnf-<244>.
EA201101523A1 (ru) Способы лечения метаболических нарушений, использующие эпиметаболические переключатели, многоаспектные внутриклеточные молекулы или факторы влияния
EP2563911A4 (de) Innovative entdeckung therapeutischer, diagnostischer und antikörperhaltiger zusammensetzungen im zusammenhang mit proteinfragmenten von alanyl-trna-synthetasen